Samuel MD - Altamira Therapeutics Chief Officer
Insider
Samuel MD is Chief Officer of Altamira Therapeutics
| Age | 72 |
| Phone | 441 295 5950 |
| Web | https://altamiratherapeutics.com |
Altamira Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.5715) % which means that it has lost $0.5715 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.6878) %, meaning that it created substantial loss on money invested by shareholders. Altamira Therapeutics' management efficiency ratios could be used to measure how well Altamira Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Altamira Therapeutics currently holds 99.66 K in liabilities with Debt to Equity (D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. Altamira Therapeutics has a current ratio of 0.75, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Altamira Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Peter Facchini | Enveric Biosciences | 61 | |
| CPA CTP | Cns Pharmaceuticals | 44 | |
| Balu Balasubramanian | Pyxis Oncology | N/A | |
| David Dornan | Elevation Oncology | 47 | |
| MBA MBA | Pyxis Oncology | 51 | |
| Nandan BS | Immix Biopharma | 63 | |
| Martina BS | Pyxis Oncology | 59 | |
| Ibrahim MD | Enveric Biosciences | 55 | |
| Jan Pinkas | Pyxis Oncology | N/A | |
| MBA IV | Enveric Biosciences | 68 | |
| DSc MSE | Immix Biopharma | 75 | |
| Robert McRae | Palisade Bio | N/A | |
| Gabriel BA | Immix Biopharma | 38 | |
| Donald Picker | Cns Pharmaceuticals | 79 | |
| Brian Sullivan | Elevation Oncology | N/A | |
| MD FAAAAI | Palisade Bio | N/A | |
| Waldemar Priebe | Cns Pharmaceuticals | N/A | |
| Joseph Ferra | Elevation Oncology | 50 | |
| MBA MD | Immix Biopharma | 49 | |
| Pamela MBA | Pyxis Oncology | 63 | |
| Avani Kanubaddi | Enveric Biosciences | 51 | |
Management Performance
| Return On Equity | -3.69 | |||
| Return On Asset | -0.57 |
Altamira Therapeutics Leadership Team
Elected by the shareholders, the Altamira Therapeutics' board of directors comprises two types of representatives: Altamira Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Altamira. The board's role is to monitor Altamira Therapeutics' management team and ensure that shareholders' interests are well served. Altamira Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Altamira Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Covadonga Paeda, Chief Officer | ||
| Covadonga Paneda, Chief Officer | ||
| Jean Lechance, Unit Bus | ||
| Thomas Meyer, President, Founder | ||
| Samuel MD, Chief Officer | ||
| Marcel CPA, Chief Officer |
Altamira Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Altamira Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.69 | |||
| Return On Asset | -0.57 | |||
| Current Valuation | 860.75 K | |||
| Shares Outstanding | 3.78 M | |||
| Shares Owned By Insiders | 0.52 % | |||
| Shares Owned By Institutions | 3.13 % | |||
| Number Of Shares Shorted | 50.63 K | |||
| Price To Book | 0.08 X | |||
| Price To Sales | 0.64 X | |||
| Gross Profit | (2.18 M) |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Other Consideration for investing in Altamira Stock
If you are still planning to invest in Altamira Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Altamira Therapeutics' history and understand the potential risks before investing.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |